25218-99-9

Basic information

• Product Name: N-(6-Bromopyridin-2-yl)acetamide
• Synonyms: N-(6-Bromopyridin-2-yl);N-(6-Bromopyridin-2-yl)acetamide;2-Acetamido-6-bromopyridine;AcetaMide,N-(6-broMo-2-pyridinyl)-
• CAS NO: 25218-99-9
• Molecular Formula: C₇H₇BrN₂O
• Molecular Weight: 215.05
• Product Categories: pharmacetical
• Mol File: 25218-99-9.mol
• Article Data: 19

Chemical Properties

• Melting Point: 157.4 °C
• Boiling Point: 389.557°C at 760 mmHg
• Flash Point: 189.398°C
• Appearance: /
• Density: 1.63g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.619
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 13.15±0.70(Predicted)
• CAS DataBase Reference: N-(6-Bromopyridin-2-yl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(6-Bromopyridin-2-yl)acetamide(25218-99-9)
• EPA Substance Registry System: N-(6-Bromopyridin-2-yl)acetamide(25218-99-9)

Safety Data

• Hazardous Substances Data: 25218-99-9(Hazardous Substances Data)

Usage

Description

N-(6-Bromopyridin-2-yl)acetamide, also known as 2-Acetamido-6-bromopyridine, is an organic compound with a molecular structure that features a bromo substituent on the pyridine ring and an amide functional group. It is a versatile chemical reagent known for its applications in the synthesis of various pharmaceutical compounds.

Uses

Used in Pharmaceutical Synthesis:
N-(6-Bromopyridin-2-yl)acetamide is used as a chemical reagent for the synthesis of diarylureas, which are allosteric modulators. These diarylureas have potential applications in the treatment of various neurological disorders and conditions by modulating the activity of specific receptors in the central nervous system.
Used in the Production of Bcl-Abl Inhibitors:
N-(6-Bromopyridin-2-yl)acetamide is also utilized in the production of novel Bcl-Abl inhibitors with flexible linkers. Bcl-Abl inhibitors are a class of drugs that target the Bcr-Abl tyrosine kinase, which is involved in the development of certain types of leukemia. The flexible linkers in these inhibitors allow for better binding and efficacy against the target protein, potentially leading to improved treatment outcomes for patients with leukemia.

InChI:InChI=1/C7H7BrN2O/c1-5(11)9-7-4-2-3-6(8)10-7/h2-4H,1H3,(H,9,10,11)

Upstream product

• 1075-62-3 N-(6-aminopyridin-2-yl)acetamide 
• 19798-81-3 2-Amino-6-bromopyridine 
• 75-36-5 acetyl chloride 
• 108-24-7 acetic anhydride 
• 127-19-5 N,N-dimethyl acetamide 
• 144100-07-2 2-bromo-6-fluoropyridine 
• 124-42-5 acetamidine hydrochloride 

Downstream Products

• 19798-81-3 2-Amino-6-bromopyridine 
• 171976-26-4 (+/-)-N,N'-<<7,7'-bis(benzyloxy)-2,2'-bis(dodecyloxy)-1,1'-binaphthalene-6,6'-diyl>dipyridine-6,2-diyl>bis(acetamide) 
• 337535-93-0 N-(6-(4-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]phenyl)-2-pyridinyl)acetamide 
• 84487-05-8 6-bromo-5-nitropyridin-2-amine 
• 1220596-29-1 benzyl 2-(6-acetamidopyridin-2-yl)ethylcarbamate 
• 1398118-13-2 ethyl 1-{4-[6-(acetylamino)-2-pyridinyl]phenyl}-3-amino-5-chloro-1H-pyrrole-2-carboxylate 
• 1398118-14-3 ethyl 1-{4-[6-(acetylamino)-2-pyridinyl]phenyl}-5-chloro-3-[({[3-(methyloxy)phenyl]amino}carbonyl)amino]-1H-pyrrole-2-carboxylate 

Relevant articles and documents

Access to 2-pyridinylamide and imidazopyridine from 2-fluoropyridine and amidine hydrochloride

Under catalyst-free conditions, an efficient method to synthesize 2-pyridinylamides has been developed, and the protocol uses inexpensive and readily available 2-fluoropyridine and amidine derivatives as the starting materials. Simultaneously, the copper-catalysed approach to imidazopyridine derivatives has been established with high chemoselectivity and regiospecificity. The results suggest that the nitrogen-heterocycles containing iodide substituents can also be compatible for the reaction via the cascade Ullmann-type coupling, and the nucleophilic substitution reaction provides the target products in a one-pot manner.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

Macrocyclic derivative of pyrazole[3,4-d]pyrimidin-3-one and pharmaceutical composition and application thereof

The present invention relates to a macrocyclic derivative of pyrazole[3,4-d]pyrimidin-3-one as shown in the formula (I) and/or a pharmaceutically acceptable salt thereof, and a composition of a compound of the formula (I) and/or a pharmaceutically acceptable salt thereof, a preparation method thereof, application thereof as a Wee1 inhibitor and application thereof as a sensitizer for cancer chemotherapy or radiotherapy. The macrocyclic derivative of pyrazole[3,4-d]pyrimidin-3-one can effectively inhibit Wee1 and related signaling pathways, and has good cancer treatment and/or relieving effect.The formula is shown in the description.